Skip to main content
Clinical Trials/CTRI/2023/06/053981
CTRI/2023/06/053981
Not yet recruiting
未知

A single centre prospective observational study to compare the outcomes & toxicities of Azacitidine plus Venetoclax (AZA plus VEN) with 3 plus 7 induction chemotherapy (IC) with Cytarabine and Daunorubicin in patients with Acute Myeloid Leukemia (AML)

Dr Manju Sengar0 sites0 target enrollmentTBD

Overview

Phase
未知
Intervention
Not specified
Conditions
Health Condition 1: C929- Myeloid leukemia, unspecified
Sponsor
Dr Manju Sengar
Status
Not yet recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Observational

Investigators

Sponsor
Dr Manju Sengar

Eligibility Criteria

Inclusion Criteria

  • 1\- Newly diagnosed patients with Acute Myeloid Leukemia (AML) of any risk group, 18 years of age or older
  • 2\- No prior therapy
  • 3\- Willing to continue treatment (induction) at TMH

Exclusion Criteria

  • 1\- Acute Promyelocytic Leukemia
  • 2\- Patients not willing to participate in the study

Outcomes

Primary Outcomes

Not specified

Similar Trials